Partial agonism, neutral antagonism, and inverse agonism at the human wild-type and constitutively active cholecystokinin-2 receptors

Molecular Pharmacology

Volumn 69, Issue 3, 2006, Pages 680-690

  Foucaud, Magali ^a,b   Tikhonova, Irina G ^a,b   Langer, Ingrid ^a,b   Escrieut, Chantal ^a,b   Dufresne, Marl̀ene ^a,b   Seva, Cathy ^a,b   Maigret, Bernard ^c   Fourmy, Daniel ^a,b,d  

^a INSERM   (France)

^b UNIVERSITÉ DE TOULOUSE   (France)

^c CNRS   (France)

^d IFR 31   (France)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2,3 DIHYDRO 1 METHYL 2 OXO 5 PHENYL 1H 1,4 BENZODIAZEPIN 3 YL) 3 (3 METHYLPHENYL)UREA; 1 [2,3 DIHYDRO 1 (2' METHYLPHENACYL) 2 OXO 5 PHENYL 1H 1,4 BENZODIAZEPIN 3 YL] 3 (3 METHYLPHENYL)UREA; CHOLECYSTOKININ B RECEPTOR; INOSITOL PHOSPHATE; ITRIGLUMIDE; PD 135158;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CHEMICAL STRUCTURE; CONTROLLED STUDY; LIGAND BINDING; MOLECULAR DYNAMICS; NONHUMAN; PHARMACOPHORE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BINDING;

ANIMALS; CERCOPITHECUS AETHIOPS; COS CELLS; HUMANS; INOSITOL PHOSPHATES; LIGANDS; MUTATION; RECEPTOR, CHOLECYSTOKININ B;

EID: 33644837205     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.105.019992     Document Type: Article

References (45)

1. Archer-Lahlou E, Escrieut C, Clerc P, Martinez J, Moroder L, Logsdon C, Kopin A, Seva C, Dufresne M, Pradayrol L, et al. (2005) Molecular mechanism underlying partial and full agonism mediated by the human cholecystokinin-1 receptor. J Biol Chem 280:10664-10674.
2. Beinborn M, Quinn SM, and Kopin AS (1998) Minor modifications of a cholecystokinin-B/gastrin receptor non-peptide antagonist confer a broad spectrum of functional properties. J Biol Chem 273:14146-14151.
3. Beinborn M, Ren Y, Blaker M, Chen C, and Kopin AS (2004) Ligand function at constitutively active receptor mutants is affected by two distinct yet interacting mechanisms. Mol Pharmacol 65:753-760.
4. Bertrand P, Bohme GA, Durieux C, Guyon C, Capet M, Jeantaud B, Boudeau P, Ducos B, Pendley CE, Martin GE, et al. (1994) Pharmacological properties of ureido-acetamides, new potent and selective non-peptide CCKB/gastrin receptor antagonists. Eur J Pharmacol 262:233-245.
5. Blaker M, Ren Y, Gordon MC, Hsu JE, Beinborn M, and Kopin AS (1998) Mutations within the cholecystokinin-B/gastrin receptor ligand 'pocket' interconvert the functions of nonpeptide agonists and antagonists. Mol Pharmacol 54:857-863.
6. Blaker M, Ren Y, Seshadri L, McBride EW, Beinborn M, and Kopin AS (2000) CCK-B/Gastrin receptor transmembrane domain mutations selectively alter synthetic agonist efficacy without affecting the activity of endogenous peptides. Mol Pharmacol 58:399-406.
7. Blevins GT Jr, van de Westerlo EM, Yule DI, and Williams JA (1994) Characterization of cholecystokinin A receptor agonist activity by a family of cholecystokinin B receptor antagonists. J Pharmacol Exp Ther 269:911-916.
8. Cerione RA, Codina J, Benovic JL, Lefkowitz RJ, Birnbaumer L, and Caron MG (1984) The mammalian beta 2-adrenergic receptor: reconstitution of functional interactions between pure receptor and pure stimulatory nucleotide binding protein of the adenylate cyclase system. Biochemistry 23:4519-4525.
9. Chao C, Ives KL, Goluszko E, Kolokoltsov AA, Davey RA, Townsend CM Jr, and Hellmich MR (2005) SRC regulates constitutive internalization and rapid resensitization of a CCK2 receptor splice variant. J Biol Chem 280:33368-33373.
10. Chopra M and Mishra A (2005) Ligand-based molecular modeling study on a chemically diverse series of cholecystokinin-B/gastrin receptor antagonists: generation of predictive model. J Chem Inf Model 45:1934-1942.
11. Colson AO, Perlman JH, Jinsi-Parimoo A, Nussenzveig DR, Osman R, and Gershengorn MC (1998) A hydrophobic cluster between transmembrane helices 5 and 6 constrains the thyrotropin-releasing hormone receptor in an inactive conformation. Mol Pharmacol 54:968-978.
12. Costa T and Herz A (1989) Antagonists with negative intrinsic activity at delta opioid receptors coupled to GTP-binding proteins. Proc Natl Acad Sci USA 86: 7321-7325.
13. Cotecchia S, Exum S, Caron MG, and Lefkowitz RJ (1990) Regions of the alpha 1-adrenergic receptor involved in coupling to phosphatidylinositol hydrolysis and enhanced sensitivity of biological function. Proc Natl Acad Sci USA 87:2896-2900.
14. Dufresne M, Seva M, and Fourmy D (2006) Cholecystokinin and gastrin receptors. Physiol Rev, in press.
15. 2A receptor determines relative efficacy. Mol Pharmacol 63:36-43.
16. Fanelli F and De Benedetti P (2005) Computational modeling approaches to structure-function analysis of G protein-coupled receptors. Chem Rev 105:3297-3351.
17. Fourmy D, Lopez P, Poirot S, Jimenez J, Dufresne M, Moroder L, Powers SP, and Vaysse N (1989) A new probe for affinity labelling pancreatic cholecystokinin receptor with minor modification of its structure. Eur J Biochem 185:397-403.
18. Gales C, Poirot M, Taillefer J, Maigret B, Martinez J, Moroder L, Escrieut C, Pradayrol L, Fourmy D, and Silvente-Poirot S (2003a) Identification of tyrosine 189 and asparagine 358 of the cholecystokinin 2 receptor in direct interaction with the crucial C-terminal amide of cholecystokinin by molecular modeling, sitedirected mutagenesis and structure/affinity studies. Mol Pharmacol 63:973-982.
19. Gales C, Sanchez D, Poirot M, Pyronnet S, Buscail L, Cussac D, Pradayrol L, Fourmy D, and Silvente-Poirot S (2003b) High tumorigenic potential of a constitutively active mutant of the cholecystokinin 2 receptor. Oncogene 22:6081-6089.
20. Herranz R (2003) Cholecystokinin antagonists: pharmacological and therapeutic potential. Med Res Rev 23:559-605.
21. Hocker M, Hughes J, Folsch UR, and Schmidt WE (1993) PD 135158, a CCKB/gastrin receptor antagonist, stimulates rat pancreatic enzyme secretion as a CCKA receptor agonist. Eur J Pharmacol 242:105-108.
22. Hughes J, Boden P, Costall B, Domeney A, Kelly E, Horwell DC, Hunter JC, Pinnock RD, and Woodruff GN (1990) Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity. Proc Natl Acad Sci USA 87:6728-6732.
23. Jagerschmidt A, Guillaume N, Roques BP, and Noble F (1998) Binding sites and transduction process of the cholecystokininB receptor: involvement of highly conserved aromatic residues of the transmembrane domains evidenced by site-directed mutagenesis. Mol Pharmacol 53:878-885.
24. Jones G, Willett P, Glen RC, Leach AR, and Taylor R (1997) Development and validation of a genetic algorithm for flexible docking. J Mol Biol 267:727-748.
25. Kalindjian SB, Bodkin MJ, Buck IM, Dunstone DJ, Low CM, McDonald IM, Pether MJ, and Steel KI (1994) A new class of non-peptidic cholecystokinin-B/ gastrin receptor antagonists based on dibenzobicyclo[2.2.2]octane. J Med Chem 37:3671-3673.
26. Kopin AS, Lee YM, McBride EW, Miller LJ, Lu M, Lin HY, Kolakowski LF Jr, and Beinborn M (1992) Expression cloning and characterization of the canine parietal cell gastrin receptor. Proc Natl Acad Sci USA 89:3605-3609.
27. Kopin AS, McBride EW, Chen C, Freidinger RM, Chen D, Zhao CM, and Beinborn M (2003) Identification of a series of CCK-2 receptor nonpeptide agonists: sensitivity to stereochemistry and a receptor point mutation. Proc Natl Acad Sci USA 100:5525-5530.
28. Kopin AS, McBride EW, Gordon MC, Quinn SM, and Beinborn M (1997) Inter- and intraspecies polymorphisms in the cholecystokinin-B/gastrin receptor alter drug efficacy. Proc Natl Acad Sci USA 94:11043-11048.
29. Kopin AS, McBride EW, Schaffer K, and Beinborn M (2000) CCK receptor polymorphisms: an illustration of emerging themes in pharmacogenomics. Trends Pharmacol Sci 21:346-353.
30. Langer I, Tikhonova IG, Travers MA, Archer-Lahlou E, Escrieut C, Maigret B, and Fourmy D (2005) Evidence that interspecies polymorphism in the human and rat cholecystokinin receptor-2 affects structure of the binding site for the endogenous agonist cholecystokinin. J Biol Chem 280:22198-22204.
31. Lotti VJ and Chang RS (1989) A new potent and selective non-peptide gastrin antagonist and brain cholecystokinin receptor (CCK-B) ligand: L-365,260. Eur J Pharmacol 162:273-280.
32. Martin-Martinez M, Marty A, Jourdan M, Escrieut C, Archer E, Gonzalez-Muniz R, Garcia-Lopez MT, Maigret B, Herranz R, and Fourmy D (2005) Combination of molecular modeling, site-directed mutagenesis and SAR studies to delineate the binding site of pyridopyrimidine antagonists on the human CCK1 receptor. J Med Chem 48:4842-4850.
33. Moroder L, Wilschowitz L, Gemeiner M, Gohring W, Knof S, Scharf R, Thamm P, Gardner JD, Solomon TE, and Wunsch E (1981) Cholecystokinin-pancreozymin synthesis. Synthesis of [28-threonine,31-norleucine]- and [28-threonine,31- leucine]cholecystokinin-pancreozymin-(25-33)-nonapeptide. Hoppe Seylers Z Physiol Chem 362:929-942.
34. Noble F, Wank SA, Crawley JN, Bradwejn J, Seroogy KB, Hamon M, and Roques BP (1999) International Union of Pharmacology. XXI. Structure, distribution and functions of cholecystokinin receptors. Pharmacol Rev 51:745-781.
35. Pommier B, Marie-Claire C, Da Nascimento S, Wang HL, Roques BP, and Noble F (2003) Further evidence that the CCK2 receptor is coupled to two transduction pathways using site-directed mutagenesis. J Neurochem 85:454-461.
36. Revel L, Mennuni L, Garofalo P, and Makovec F (1998) CR 2945: a novel CCKB receptor antagonist with anxiolytic-like activity. Behav Pharmacol 9:183-194.
37. Satoh M, Kondoh Y, Okamoto Y, Nishida A, Miyata K, Ohta M, Mase T, and Murase K (1995) New 1,4-benzodiazepin-2-one derivatives as gastrin/ cholecystokinin-B antagonists. Chem Pharm Bull (Tokyo) 43:2159-2167.
38. Schmassmann A, Garner A, Flogerzi B, Hasan MY, Sanner M, Varga L, and Halter F (1994) Cholecystokinin type B receptor antagonist PD-136,450 is a partial secretory agonist in the stomach and a full agonist in the pancreas of the rat. Gut 35:270-274.
39. Seifert R and Wenzel-Seifert K (2002) Constitutive activity of G-protein-coupled receptors: cause of disease and common property of wild-type receptors. Naunyn-Schmiedeberg's Arch Pharmacol 366:381-416.
40. Silvente-Poirot S, Dufresne M, Vaysse N, and Fourmy D (1993) The peripheral cholecystokinin receptors. Eur J Biochem 215:513-529.
41. Silvente-Poirot S, Escrieut C, Gales C, Fehrentz JA, Escherich A, Wank SA, Martinez J, Moroder L, Maigret B, Bouisson M, et al. (1999) Evidence for a direct interaction between the penultimate aspartic acid of cholecystokinin and histidine 207, located in the second extracellular loop of the cholecystokinin B receptor. J Biol Chem 274:23191-23197.
42. Soudijn W, van Wijngaarden I, and IJzerman AP (2005) Structure-activity relationships of inverse agonists for G-protein-coupled receptors. Med Res Rev 25:398-426.
43. Ursini A, Capelli AM, Carr RA, Cassara P, Corsi M, Curcuruto O, Curotto G, Dal Cin M, Davalli S, Donati D, et al. (2000) Synthesis and SAR of new 5-phenyl-3-ureido-1,5-benzodiazepines as cholecystokinin-B receptor antagonists. J Med Chem 43:3596-3613.
44. Visiers I, Ballesteros JA, and Weinstein H (2002) Three-dimensional representations of G protein-coupled receptor structures and mechanisms. Methods Enzymol 343:329-371.
45. Wank SA, Pisegna JR, and de Weerth A (1992) Brain and gastrointestinal cholecystokinin receptor family: structure and functional expression. Proc Natl Acad Sci USA 89:8691-8695.